Tpoxx (tecovirimat) from SIGA Technologies is a unique small-molecule drug. In 2018, it became the first drug to win an FDA indication for smallpox. While smallpox was eradicated around 1980s, governments across the world have worried that the variola virus that causes the disease could provide the basis for bioweapons.
The U.S. maintains a stockpile of 1.7 million oral doses of the drug as part of the Strategic National Stockpile.
In August, the White House announced that it would ramp up supplies of the drug to fight the U.S. monkeypox outbreak, making an additional 50,000 doses available to states and local governments.
Filed Under: Infectious Disease